Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRE-CF
NCT02443688Phase 2Completed
- Sponsor
- Celtaxsys, Inc.
- Start
- Oct 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of acebilustat in cystic fibrosis (CF) (3 arms), sponsored by Celtaxsys, Inc. Primary endpoint: Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted at 48 weeks. Started Oct 2015; status: completed.
02
Drugs
acebilustat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02443688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443688.